I am almost certain that no other director of an NCI-designated cancer center can claim the distinction of having had a gun pulled on them by police.
Nicole Kuderer and colleagues are to be congratulated for their report—in The Lancet and at the ASCO 2020 Annual Meeting—on the impact of COVID-19 on a cohort of patients with cancer.
As the healthcare system faces the onslaught of the novel coronavirus SARS-CoV-2, clinicians caring for individuals with cancer face the challenge of a wide gap in knowledge needed to guide decision-making.
On a chaotic COVID weekend two months ago, a friend’s child (a young, talented black and Latino student athlete) came home from college not feeling well. The young man’s mother, an executive administrative assistant, called off work to stay home with him because of his, as she described, “full-blown flu-like symptoms.”
The global pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to expectations of global deaths numbering in the hundreds of thousands. Promising therapeutic strategies have emerged slower than society would prefer. COVID-related deaths in the United States exceed 86,000 as of this writing, with projections as high as 134,000.
Prior to the COVID-19 pandemic, NCI estimated that about 3% to 5% of adult cancer patients participated in clinical trials.
In the past decade, there has been a growing interest in capitalizing on advances in information technology to provide quality and patient-centered care to cancer patients and survivors outside a hospital or clinic setting.
The COVID-19 pandemic has been catastrophic to health care in the US.
As part of responding to the COVID-19 pandemic, hospitals across the nation had dramatically reduced their surgery schedules when UC Davis cancer patient Marlene Blake had surgery for breast cancer in March.
This pandemic has affected a lot of people, both physicians and patients, physically as well as emotionally.
